Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.
about
Aspergillus fumigatus invasion increases with progressive airway ischemiaIn vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosisEarly-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulansInhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.The pharmacology and clinical use of caspofungin.CNS pharmacokinetics of antifungal agents.Animal models: an important tool in mycology.Strain-dependent variation in 18S ribosomal DNA Copy numbers in Aspergillus fumigatusCaspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.RNA-Seq Profile Reveals Th-1 and Th-17-Type of Immune Responses in Mice Infected Systemically with Aspergillus fumigatus.
P2860
Q27304352-1F0DE807-F07B-4966-91DF-19D2AEABA92BQ28542402-A74D7726-1816-453A-B2FA-A04AE35B8335Q33366929-6B18E55B-A142-470E-A389-36E965EF6B3EQ33689767-5A3A9F0B-119B-4223-A5AF-203CC6A7EE3FQ35215384-D1949DAA-0231-4C2D-8C4E-661EC4E72D63Q35739749-EDD6F3E4-7426-46E8-A1CB-8E42275F1985Q36788428-240A769C-AC1C-4F45-8356-D36400194559Q36909333-B34C8235-9ECA-4C39-86D8-25DCF17973A9Q37008692-673F1B68-16AD-4F9B-977C-61E254286E3DQ37191546-FC23E04D-A06E-49D9-9135-2455ACF2D020Q38586680-4D83955D-1A13-4E1D-8374-2E8AA4C43623Q40180378-AD700F9C-9975-4602-8902-F64BA65B1E8FQ40667866-84F6535B-95B4-46DF-86D8-5D6E60D459B8Q42217419-374FFFF4-C488-4211-9369-7C708A8FB29CQ45957532-4ADBF1BC-CBCC-44E2-9F66-D061E25B257DQ54262970-A044EF75-263C-4476-AB63-7992CFE6A408
P2860
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@en
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@nl
type
label
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@en
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@nl
prefLabel
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@en
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@nl
P2093
P2860
P1476
Efficacy of caspofungin agains ...... by TaqMan PCR and CFU methods.
@en
P2093
David A Stevens
Gaurav Singh
Jackie Imai
Karl V Clemons
P2860
P304
P356
10.1128/AAC.49.4.1369-1376.2005
P407
P577
2005-04-01T00:00:00Z